2-[(5-hex-1-yn-1-ylfuran-2-yl)carbonyl]-N-methylhydrazinecarbothioamide

This compound is a synthetic small molecule belonging to the class of furoic acid derivatives. It was developed as part of rational drug design efforts targeting the S100B-p53 protein-protein interaction, with the aim of restoring wild-type p53 function in malignant melanoma and potentially other cancers. Structural studies have shown that it binds to Ca(2+)-S100B at a specific hydrophobic pocket, interfering with S100B's interaction with p53. This mechanism may enable reactivation of tumor suppressor pathways in cancer cells where S100B is overexpressed[7][9]. There are no known clinical trials or approved indications for this compound, and it has not been approved by any major regulatory agency[3].

Other names

2-[5-(1-Hexyn-1-yl)-2-furoyl]-N-methylhydrazinecarbothioamide5-(hex-1-yn-1-yl)-N-[methylcarbamothioyl]amino]furan–2-carboxamide5-(hex–1–yn–1–yl)–N–[(methylcarbamothioyl)amino]furan–2-carboxamide3gk1 (structural code)